Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent p-glycoprotein-mediated multidrug resistance

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2592-2599

  Roy, Aniruddha ^a   Murakami, Mami ^a   Ernsting, Mark J ^a,b   Hoang, Bryan ^a   Undzys, Elijus ^a   Li, Shyh Dar ^a,c,d  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b RYERSON UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

carboxymethylcellulose; docetaxel; drug delivery; multidrug resistance; nanoparticles; P glycoprotein

Indexed keywords

CARBOXYMETHYLCELLULOSE; CELLAX; DOCETAXEL; GLYCOPROTEIN P INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NANOPARTICLE; POLYMER; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; IC50; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NONOBESE DIABETIC MOUSE; PHENOTYPE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOXYMETHYLCELLULOSE SODIUM; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; P-GLYCOPROTEIN; PHENOTYPE; POLYMERS; RNA, MESSENGER; TAXOIDS;

EID: 84905454913     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400643p     Document Type: Article

References (22)

1. Yusuf, R. Z.; Duan, Z.; Lamendola, D. E.; Penson, R. T.; Seiden, M. V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation Curr. Cancer Drug Targets 2003, 3 (1) 1-19
2. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2 (1) 48-58
3. Klein, I.; Sarkadi, B.; Varadi, A. An inventory of the human ABC proteins Biochim. Biophys. Acta 1999, 1461 (2) 237-262
4. Baekelandt, M. M.; Holm, R.; Nesland, J. M.; Trope, C. G.; Kristensen, G. B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res. 2000, 20 (2B) 1061-1067
5. Kamazawa, S.; Kigawa, J.; Kanamori, Y.; Itamochi, H.; Sato, S.; Iba, T.; Terakawa, N. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer Gynecol. Oncol. 2002, 86 (2) 171-176
6. Li, R.; Zou, H.; Xiao, H.; Wu, R. Carbon nanotubes as intracellular carriers for multidrug resistant cells studied by capillary electrophoresis- laser-induced fluorescence Methods Mol. Biol. 2010, 625, 153-168
7. Liu, Y.; Huang, L.; Liu, F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer Mol. Pharmaceutics 2010, 7 (3) 863-869
8. Kabanov, A. V.; Batrakova, E. V.; Alakhov, V. Y. Pluronic block copolymers for overcoming drug resistance in cancer Adv. Drug. Delivery Rev. 2002, 54 (5) 759-779
9. Ma, P.; Dong, X.; Swadley, C. L.; Gupte, A.; Leggas, M.; Ledebur, H. C.; Mumper, R. J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 2009, 5 (2) 151-161
10. Wang, D.; Tang, J.; Wang, Y.; Ramishetti, S.; Fu, Q.; Racette, K.; Liu, F. Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer Mol. Pharmaceutics 2013, 10 (4) 1465-1469
11. Ernsting, M. J.; Tang, W. L.; MacCallum, N.; Li, S. D. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells Bioconjugate Chem. 2011, 22 (12) 2474-2486
12. Ernsting, M. J.; Murakami, M.; Undzys, E.; Aman, A.; Press, B.; Li, S. D. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases J. Controlled Release 2012, 162 (3) 575-581
13. Ernsting, M. J.; Tang, W. L.; Maccallum, N. W.; Li, S. D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models Biomaterials 2012, 33 (5) 1445-1454
14. Patel, K. J.; Tannock, I. F. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors BMC Cancer 2009, 9, 356
15. Geney, R.; Ungureanu l, M.; Li, D.; Ojima, I. Overcoming multidrug resistance in taxane chemotherapy Clin. Chem. Lab. Med. 2002, 40 (9) 918-925
16. Wang, Y.; Chen, Q.; Jin, S.; Deng, W.; Li, S.; Tong, Q.; Chen, Y. Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells Scand. J. Gastroenterol. 2012, 47 (7) 802-808
17. Smoter, M.; Bodnar, L.; Duchnowska, R.; Stec, R.; Grala, B.; Szczylik, C. The role of Tau protein in resistance to paclitaxel Cancer Chemother. Pharmacol. 2011, 68 (3) 553-557
18. Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F. O.; Ferrandina, G.; Scambia, G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin. Cancer Res. 2005, 11 (1) 298-305
19. Castells, M.; Thibault, B.; Delord, J. P.; Couderc, B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death Int. J. Mol. Sci. 2012, 13 (8) 9545-9571
20. Ho, E. A.; Soo, P. L.; Allen, C.; Piquette-Miller, M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors J. Controlled Release 2007, 117 (1) 20-27
21. De Souza, R.; Zahedi, P.; Badame, R. M.; Allen, C.; Piquette-Miller, M. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol. Cancer Ther. 2011, 10 (7) 1289-1299
22. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Xue, H. Y.; Babakhanian, K.; Wu, X. Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 2006, 317 (3) 1372-1381